Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSMirodenafil is a phosphodiesterase 5 (PDE5) inhibitor.1 It increases penile intracavernosal pressure (ICP) in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) and in a rat model of cavernosal nerve injury when administered at doses of 1 and 10 mg/kg, respectively.1,2 Mirodenafil (4 mg/kg per day) decreases bladder wall submucosal fibrosis and degeneration in a rat model of chronic bladder ischemia.3 It also decreases bladder overactivity in a female rat model of partial bladder outlet obstruction.4
WARNING This product is not for human or veterinary use.
1. Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes. Int. J. Androl. 34(5 Pt 2), e468-e474 (2011).
2. The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. Int. J. Impot. Res. 22(5), 291-297 (2010).
3. Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats. Int. Neurourol. J. 19(1), 19-26 (2015).
4. Effects of mirodenafil, a phosphodiesterase-